Cilnidipine (BioDeep_00000398866)

   

natural product


代谢物信息卡片


Cilnidipine

化学式: C27H28N2O7 (492.1896)
中文名称: 西尼地平
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC=C(C=C1C2C(=C(NC(=C2C(OCCOC)=O)C)C)C(OC/C=C/C3=CC=CC=C3)=O)[N+](=O)[O-]
InChI: InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+

描述信息

C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

1 个代谢物同义名

Cilnidipine



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Eri Harada, Kazumi Sugino, Megumi Aimoto, Akira Takahara. Effects of the L/N-Type Ca2+ Channel Blocker Cilnidipine on the Cardiac Histological Remodelling and Inducibility of Atrial Fibrillation in High-Salt-Fed Rats. Biological & pharmaceutical bulletin. 2021 May; 44(5):707-713. doi: 10.1248/bpb.b21-00024. [PMID: 33642455]
  • Rimpy Diwan, Shareef Khan, Punna Rao Ravi. Comparative study of cilnidipine loaded PLGA nanoparticles: process optimization by DoE, physico-chemical characterization and in vivo evaluation. Drug delivery and translational research. 2020 10; 10(5):1442-1458. doi: 10.1007/s13346-020-00732-5. [PMID: 32329025]
  • Fernanda C Cardoso, Marie-Adeline Marliac, Chloe Geoffroy, Matthieu Schmit, Anjie Bispat, Richard J Lewis, Kellie L Tuck, Peter J Duggan. The neuronal calcium ion channel activity of constrained analogues of MONIRO-1. Bioorganic & medicinal chemistry. 2020 09; 28(18):115655. doi: 10.1016/j.bmc.2020.115655. [PMID: 32828422]
  • Shrilaxmi Bagali, Savitri M Nerune, R Chandramouli Reddy, Saeed M Yendigeri, Bheemshetty S Patil, Akram A Naikwadi, Raghavendra V Kulkarni, Kusal K Das. Low oxygen microenvironment and cardiovascular remodeling: Role of dual L/N.type Ca2+ channel blocker. Indian journal of pharmacology. 2020 Sep; 52(5):383-391. doi: 10.4103/ijp.ijp_136_20. [PMID: 33283770]
  • Rimpy Diwan, Punna Rao Ravi, Nikita Shantaram Pathare, Vidushi Aggarwal. Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. Colloids and surfaces. B, Biointerfaces. 2020 Sep; 193(?):111073. doi: 10.1016/j.colsurfb.2020.111073. [PMID: 32388122]
  • Saori Matsuda, Shinobu Nagahama, Yoshiki Kurose, Maki Wakabayashi, Hitoshi Sugii, Tsukasa Teshima, Noriyuki Suzuki, Kazuomi Kario. A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations. Clinical and experimental hypertension (New York, N.Y. : 1993). 2020 Aug; 42(6):502-511. doi: 10.1080/10641963.2020.1714641. [PMID: 31964180]
  • Kazuko Tajiri, Jean-Baptiste Guichard, Xiaoyan Qi, Feng Xiong, Patrice Naud, Jean-Claude Tardif, Antoine Da Costa, Kazutaka Aonuma, Stanley Nattel. An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. Cardiovascular research. 2019 Dec; 115(14):1975-1985. doi: 10.1093/cvr/cvz136. [PMID: 31119260]
  • Takahiro Kanai, Kazuhiro Shiizaki, Hiroyuki Betsui, Jun Aoyagi, Takanori Yamagata. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts. CEN case reports. 2018 11; 7(2):259-263. doi: 10.1007/s13730-018-0339-9. [PMID: 29767399]
  • Abdel-Motaal Fouda, Amany R Youssef, Osama Sharaf Eldin. Comparative study of amlodipine vs. cilnidipine for the prevention of hepatic ischemia-reperfusion injury in rat model. Fundamental & clinical pharmacology. 2018 Apr; 32(2):163-173. doi: 10.1111/fcp.12335. [PMID: 29172244]
  • Satoko Nozato, Koichi Yamamoto, Yoichi Nozato, Masao Takeda, Kazuhiro Hongyo, Miyuki Takeya, Hiroshi Akasaka, Yoichi Takami, Yasushi Takeya, Ken Sugimoto, Norihisa Ito, Hiromi Rakugi. Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension. 2018 Apr; 41(4):290-298. doi: 10.1038/s41440-018-0018-4. [PMID: 29449705]
  • You-Cheol Hwang, Kun-Ho Yoon, Bong-Soo Cha, Kwan-Woo Lee, Hak Chul Jang, Kyung Wan Min, Choon Hee Chung, Moon-Kyu Lee. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. International journal of clinical practice. 2017 Sep; 71(9):. doi: 10.1111/ijcp.12987. [PMID: 28840637]
  • Xin Cao, Yuji Nakamura, Takeshi Wada, Hiroko Izumi-Nakaseko, Kentaro Ando, Atsushi Sugiyama. L/N-type Ca2+ channels blocker cilnidipine ameliorated the repolarization abnormality in a chronic hemodialysis patient. Heart and vessels. 2017 Jan; 32(1):105-108. doi: 10.1007/s00380-016-0865-3. [PMID: 27325120]
  • Takeshi Iida, Satoshi Morimoto, Yoshifumi Amari, Takashi Ando, Atsuhiro Ichihara. Effects of L- and N-Type Ca Channel Blocker Cilnidipine on Changes in Heart Rate and QT Interval During Dialysis. Kidney & blood pressure research. 2017; 42(5):933-941. doi: 10.1159/000485083. [PMID: 29166643]
  • Tadashi Konoshita, Saori Kaeriyama, Machi Urabe, Takahiro Nakaya, Mika Yamada, Mai Ichikawa, Katsushi Yamamoto, Satsuki Sato, Michiko Imagawa, Miki Fujii, Yasukazu Makino, Yasuo Zenimaru, Shigeyuki Wakahara, Jinya Suzuki, Tamotsu Ishizuka, Hiroyuki Nakamura. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone. Bioscience reports. 2016 10; 36(5):. doi: 10.1042/bsr20160129. [PMID: 27515419]
  • Man Liu, Ming Deng, Dan Zhang, Xiaolin Wang, Jingyi Ma, Hongna Zhao, Lina Zhang, Yang Tong, Huichen Liu. A chiral LC-MS/MS method for the stereospecific determination of efonidipine in human plasma. Journal of pharmaceutical and biomedical analysis. 2016 Apr; 122(?):35-41. doi: 10.1016/j.jpba.2016.01.039. [PMID: 26845200]
  • Mukesh Madhukar Shete. Cilnidipine: Next Generation Calcium Channel Blocker. The Journal of the Association of Physicians of India. 2016 Apr; 64(4):95-99. doi: NULL. [PMID: 27734656]
  • Shizuka Aritomi, Eri Harada, Kazumi Sugino, Mai Nishimura, Tarou Nakamura, Akira Takahara. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats. Clinical and experimental pharmacology & physiology. 2015 Apr; 42(4):344-52. doi: 10.1111/1440-1681.12360. [PMID: 25582553]
  • Daniel Duda-Seiman, Corina Duda-Seiman, Florin Borcan, Livia-Cristina Borcan, Silvia Mancas, Speranta Avram. Calcium Channel Blockers--Benefits Upon Vascular Biology in Hypertensive Patients. Cardiovascular & hematological agents in medicinal chemistry. 2015; 13(1):54-62. doi: 10.2174/187152571301150730115442. [PMID: 26245661]
  • Masami Tanaka, Risa Sekioka, Takeshi Nishimura, Atsuhiro Ichihara, Hiroshi Itoh. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels. Diabetes research and clinical practice. 2014 Dec; 106(3):504-10. doi: 10.1016/j.diabres.2014.09.056. [PMID: 25458339]
  • Shunya Uchida, Masato Takahashi, Masahiro Sugawara, Tomoaki Saito, Kazuhiko Nakai, Masami Fujita, Koichi Mochizuki, Isu Shin, Takashi Morita, Tomoyuki Hikita, Hironao Itakura, Yuko Takahashi, Shigeki Mizuno, Yasumi Ohno, Kageki Ito, Takafumi Ito, Masayoshi Soma. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). Journal of clinical hypertension (Greenwich, Conn.). 2014 Oct; 16(10):746-53. doi: 10.1111/jch.12412. [PMID: 25264215]
  • Chia-Wen Hsu, Jinghua Zhao, Ruili Huang, Jui-Hua Hsieh, Jon Hamm, Xiaoqing Chang, Keith Houck, Menghang Xia. Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Scientific reports. 2014 Sep; 4(?):6437. doi: 10.1038/srep06437. [PMID: 25257666]
  • Jieon Lee, Howard Lee, Kyungho Jang, Kyoung Soo Lim, Dongseong Shin, Kyung-Sang Yu. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug design, development and therapy. 2014; 8(?):1781-8. doi: 10.2147/dddt.s68574. [PMID: 25336921]
  • Kentaro Yano, Shinobu Takimoto, Toshimitsu Motegi, Takumi Tomono, Mihoko Hagiwara, Yoko Idota, Kaori Morimoto, Akira Takahara, Takuo Ogihara. Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain. Drug metabolism and pharmacokinetics. 2014; 29(3):254-8. doi: 10.2133/dmpk.dmpk-13-rg-072. [PMID: 24366438]
  • Tomohiko Kanaoka, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Tetsuya Fujikawa, Yuko Tsurumi-Ikeya, Akinobu Maeda, Mai Yanagi, Yoshiyuki Toya, Satoshi Umemura. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease. International journal of molecular sciences. 2013 Aug; 14(8):16866-81. doi: 10.3390/ijms140816866. [PMID: 23959116]
  • Masanori Abe, Noriaki Maruyama, Hiroko Suzuki, Atsushi Inoshita, Yoshinori Yoshida, Kazuyoshi Okada, Masayoshi Soma. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart and vessels. 2013 Jul; 28(4):480-9. doi: 10.1007/s00380-012-0274-1. [PMID: 22914905]
  • Tadashi Konoshita, Yasukazu Makino, Tomoko Kimura, Miki Fujii, Norihiro Morikawa, Shigeyuki Wakahara, Kenichiro Arakawa, Isao Inoki, Hiroyuki Nakamura, Isamu Miyamori. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers. International journal of cardiology. 2013 Jun; 166(2):448-52. doi: 10.1016/j.ijcard.2011.10.133. [PMID: 22112682]
  • Shinji Takai, Denan Jin, Shizuka Aritomi, Kazumi Niinuma, Mizuo Miyazaki. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertension research : official journal of the Japanese Society of Hypertension. 2013 Apr; 36(4):342-8. doi: 10.1038/hr.2012.187. [PMID: 23190689]
  • Keiichiro Mishima, Akito Maeshima, Masaaki Miya, Noriyuki Sakurai, Hidekazu Ikeuchi, Keiju Hiromura, Yoshihisa Nojima. Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats. American journal of physiology. Renal physiology. 2013 Mar; 304(6):F665-73. doi: 10.1152/ajprenal.00561.2012. [PMID: 23324177]
  • Shizuka Aritomi, Kazumi Niinuma, Tetsuya Ogawa, Tomoyuki Konda, Kosaku Nitta. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. Clinical and experimental nephrology. 2013 Feb; 17(1):41-50. doi: 10.1007/s10157-012-0677-4. [PMID: 23011292]
  • Katsuayuki Ando, Kenji Ueshima, Sachiko Tanaka, Shinji Kosugi, Tosiya Sato, Hiroaki Matsuoka, Kazuwa Nakao, Toshiro Fujita. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. International journal of medical sciences. 2013; 10(9):1209-16. doi: 10.7150/ijms.5508. [PMID: 23935398]
  • Chika Ogura, Koh Ono, Shoichi Miyamoto, Akiko Ikai, Satoko Mitani, Naozo Sugimoto, Shiro Tanaka, Masatoshi Fujita. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension. Blood pressure. 2012 Dec; 21(6):367-71. doi: 10.3109/08037051.2012.694200. [PMID: 22747420]
  • Takeshi Soeki, Mitsuhiro Kitani, Kenya Kusunose, Shusuke Yagi, Yoshio Taketani, Kunihiko Koshiba, Tetsuzo Wakatsuki, Shunsuke Orino, Kazuhiro Kawano, Masataka Sata. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension. 2012 Nov; 35(11):1058-62. doi: 10.1038/hr.2012.96. [PMID: 22763473]
  • Shizuka Aritomi, Tomoyuki Konda, Michihiro Yoshimura. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart and vessels. 2012 Jul; 27(4):419-23. doi: 10.1007/s00380-011-0191-8. [PMID: 21989861]
  • Toshihiro Hamada, Kensaku Yamada, Einosuke Mizuta, Arisa Watanabe, Tomohiro Osaki, Katsunori Ishida, Akira Hasegawa, Shinji Sakata, Mutsuo Mishima, Kazuhide Ogino, Yoshihito Nosaka, Satoshi Miyazaki, Akira Ohtahara, Haruaki Ninomiya, Masahiko Kato, Akio Yoshida, Shin-ichi Taniguchi, Kazuhiro Yamamoto, Ichiro Hisatome. Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993). 2012; 34(7):470-3. doi: 10.3109/10641963.2012.666600. [PMID: 22681507]
  • T Hatta, K Takeda, Y Shiotsu, C Sugishita, T Adachi, T Kimura, K Sonomura, T Kusaba, N Kishimioto, H Narumiya, S Tanda, K Tamagaki, K Yamada, H Kameyama, H Kido, S Harada, Y Bito, J Moriguchi, S Morimoto, M Okigaki, H Itoh, Y Mori, T Nakata, K Maki, S Sasaki, K Sawada, H Matsubara. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study. The Journal of international medical research. 2012; 40(4):1417-28. doi: 10.1177/147323001204000420. [PMID: 22971493]
  • Hiroe Toba, Mamiko Yoshida, Chisato Tojo, Arisa Nakano, Yuko Oshima, Yushi Kojima, Kazuki Noda, Jiahong Wang, Miyuki Kobara, Tetsuo Nakata. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertension research : official journal of the Japanese Society of Hypertension. 2011 Apr; 34(4):521-9. doi: 10.1038/hr.2010.279. [PMID: 21270815]
  • Li Fan, Qin Yang, Xiao-Qiu Xiao, Kevin L Grove, Yu Huang, Zhi-Wu Chen, Anthony Furnary, Guo-Wei He. Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. The Journal of thoracic and cardiovascular surgery. 2011 Apr; 141(4):1063-9. doi: 10.1016/j.jtcvs.2010.01.048. [PMID: 20599230]
  • Takashi Masuda, Misao N Ogura, Tatsumi Moriya, Naonobu Takahira, Takuya Matsumoto, Toshiki Kutsuna, Miyako Hara, Naoko Aiba, Chiharu Noda, Tohru Izumi. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. Cardiovascular therapeutics. 2011 Feb; 29(1):46-53. doi: 10.1111/j.1755-5922.2009.00126.x. [PMID: 20337636]
  • Hiroaki Matsuoka, Katsuyuki Ando, Kenji Ueshima, Tetsuya Babazono, Kazuomi Kario, Shiro Tanaka, Kazuwa Nakao, Toshiro Fujita. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. Clinical and experimental hypertension (New York, N.Y. : 1993). 2011; 33(7):455-62. doi: 10.3109/10641963.2010.549271. [PMID: 21649534]
  • Shizuka Aritomi, Kazumi Niinuma, Tetsuya Ogawa, Tomoyuki Konda, Kosaku Nitta. Effects of an N-type calcium antagonist on angiotensin II-renin feedback. American journal of nephrology. 2011; 33(2):168-75. doi: 10.1159/000323969. [PMID: 21293118]
  • Shizuka Aritomi, Hajime Koganei, Hirotaka Wagatsuma, Akira Mitsui, Tetsuya Ogawa, Kosaku Nitta, Tomoyuki Konda. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart and vessels. 2010 Nov; 25(6):549-55. doi: 10.1007/s00380-010-0005-4. [PMID: 20922532]
  • Tadashi Konoshita, Yasukazu Makino, Tomoko Kimura, Miki Fujii, Shigeyuki Wakahara, Kenichiro Arakawa, Isao Inoki, Hiroyuki Nakamura, Isamu Miyamori. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. Journal of hypertension. 2010 Oct; 28(10):2156-60. doi: 10.1097/hjh.0b013e32833d01dd. [PMID: 20625317]
  • Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama, Shiro Matsumoto, Takashi Maruyama, Takayuki Fujita, Koichi Matsumoto, Masayoshi Soma. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert opinion on investigational drugs. 2010 Sep; 19(9):1027-37. doi: 10.1517/13543784.2010.505918. [PMID: 20649501]
  • Yu-Yan Fan, Masakazu Kohno, Daisuke Nakano, Hiroyuki Ohsaki, Hiroyuki Kobori, Diah Suwarni, Naro Ohashi, Hirofumi Hitomi, Katsuhiko Asanuma, Takahisa Noma, Yasuhiko Tomino, Toshiro Fujita, Akira Nishiyama. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. Journal of hypertension. 2010 May; 28(5):1034-43. doi: 10.1097/hjh.0b013e328336ade3. [PMID: 20411599]
  • M Tanaka. The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes. The Journal of international medical research. 2010 Mar; 38(2):602-10. doi: 10.1177/147323001003800222. [PMID: 20515573]
  • Takaaki Nakatsu, Shinji Toyonaga, Keiichi Mashima, Yoko Yuki, Aya Nishitani, Hiroko Ogawa, Toru Miyoshi, Satoshi Hirohata, Reishi Izumi, Shozo Kusachi. Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis. Clinical drug investigation. 2010; 30(10):699-706. doi: 10.2165/11538510-000000000-00000. [PMID: 20701401]
  • Yoshikazu Miwa, Takuya Tsuchihashi, Yuko Ohta, Mitsuhiro Tominaga, Yuhei Kawano, Toshiyuki Sasaguri, Michio Ueno, Hiroaki Matsuoka. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection. Clinical and experimental hypertension (New York, N.Y. : 1993). 2010; 32(6):400-5. doi: 10.3109/10641961003667914. [PMID: 20828221]
  • A Takahara, Y Nakamura, H Wagatsuma, S Aritomi, A Nakayama, Y Satoh, Y Akie, A Sugiyama. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. British journal of pharmacology. 2009 Nov; 158(5):1366-74. doi: 10.1111/j.1476-5381.2009.00407.x. [PMID: 19785655]
  • Yasuko Aota, Satoshi Morimoto, Takao Sakuma, Tatsuyori Morita, Fusakazu Jo, Nobuyuki Takahashi, Minoru Maehara, Koshi Ikeda, Satoshi Sawada, Toshiji Iwasaka. Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla. Hypertension research : official journal of the Japanese Society of Hypertension. 2009 Aug; 32(8):700-5. doi: 10.1038/hr.2009.80. [PMID: 19521420]
  • Keiichi Hishikawa, Osamu Takase, Mana Idei, Toshiro Fujita, Toshiro Fujito. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney international. 2009 Jul; 76(2):230-1. doi: 10.1038/ki.2009.146. [PMID: 19564858]
  • Kayoko Takashima, Chizuru Nishiyama, Nobuhiko Arisaka, Tetsuaki Takahashi, Shinji Souma, Miyuki Tsuda, Morimichi Hayashi, Hiroko Kasahara, Hirokazu Kodama, Toru Tamura, Makoto Murakami, Junji Kuroda, Fumiyasu Sato. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats. Arzneimittel-Forschung. 2009; 59(2):79-85. doi: 10.1055/s-0031-1296368. [PMID: 19338138]
  • Tomoyuki Konda, Azusa Enomoto, Shizuka Aritomi, Kazumi Niinuma, Hajime Koganei, Tetsuya Ogawa, Kosaku Nitta. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. American journal of nephrology. 2009; 30(2):155-61. doi: 10.1159/000210396. [PMID: 19325231]
  • Yuusuke Konno, Kenjiro Kimura. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. International heart journal. 2008 Nov; 49(6):723-32. doi: 10.1536/ihj.49.723. [PMID: 19075488]
  • J A Staessen. Antiproteinuric effects of cilnidipine. Kidney international. 2008 May; 73(9):1095; author reply 1095-6. doi: 10.1038/ki.2008.49. [PMID: 18414444]
  • Heon-Woo Lee, Ji-Hyung Seo, Hyun-Su Lee, Seo-Young Jeong, Young-Wuk Cho, Kyung-Tae Lee. Development of a liquid chromatography/negative-ion electrospray tandem mass spectrometry assay for the determination of cilnidipine in human plasma and its application to a bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Feb; 862(1-2):246-51. doi: 10.1016/j.jchromb.2007.11.016. [PMID: 18155975]
  • T Fujita, K Ando, H Nishimura, T Ideura, G Yasuda, M Isshiki, K Takahashi. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney international. 2007 Dec; 72(12):1543-9. doi: 10.1038/sj.ki.5002623. [PMID: 17943080]
  • Tsuyoshi Shiga, Yuichiro Yamada, Naoki Matsuda, Takanori Tanaka, Akinori Urae, Masayuki Hashiguchi, Nobuhisa Hagiwara, Hiroshi Kasanuki. Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart and vessels. 2007 Nov; 22(6):404-9. doi: 10.1007/s00380-007-0984-y. [PMID: 18043999]
  • Satoshi Morimoto, Yutaka Yano, Kei Maki, Toshiji Iwasaka. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. Journal of hypertension. 2007 Oct; 25(10):2178-83. doi: 10.1097/hjh.0b013e3282c2fa62. [PMID: 17885563]
  • Xianhua Zhang, Suodi Zhai, Rongsheng Zhao, Jin Ouyang, Xiaoguang Li, Willy R G Baeyens. Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. Analytica chimica acta. 2007 Sep; 600(1-2):142-6. doi: 10.1016/j.aca.2006.11.072. [PMID: 17903476]
  • Tomomi Fujisawa, Hiroshi Ikegami, Shinsuke Noso, Yoshihisa Hiromine, Yumiko Kawabata, Masanori Nishino, Kazuaki Asano, Toshio Ogihara. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. Journal of diabetes and its complications. 2007 Jul; 21(4):252-7. doi: 10.1016/j.jdiacomp.2006.06.001. [PMID: 17616356]
  • Hiroaki Seino, Shuichi Miyaguchi, Toshiro Yamazaki, Setsu Ota, Ryuji Yabe, Susumu Suzuki. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine. Arzneimittel-Forschung. 2007; 57(8):526-31. doi: 10.1055/s-0031-1296643. [PMID: 17915639]
  • K Katayama, S Nomura, H Ishikawa, T Murata, S Koyabu, T Nakano. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney international. 2006 Jul; 70(1):151-6. doi: 10.1038/sj.ki.5000349. [PMID: 16710356]
  • Tomoyuki Konda, Azusa Enomoto, Akira Takahara, Hiroshi Yamamoto. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biological & pharmaceutical bulletin. 2006 May; 29(5):933-7. doi: 10.1248/bpb.29.933. [PMID: 16651722]
  • Takuya Tsuchihashi, Michio Ueno, Mitsuhiro Tominaga, Tomoko Kajioka, Uran Onaka, Kimika Eto, Kenichi Goto. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clinical and experimental hypertension (New York, N.Y. : 1993). 2005 Nov; 27(8):583-91. doi: 10.1080/10641960500298558. [PMID: 16303635]
  • Tomoyuki Konda, Azusa Enomoto, Junko Matsushita, Akira Takahara, Toshiki Moriyama. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron. Physiology. 2005; 101(1):p1-13. doi: 10.1159/000085713. [PMID: 15886499]
  • Akira Takahara, Atsushi Sugiyama, Yoshioki Satoh, Yuji Nakamura, Keitaro Hashimoto. Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. Journal of pharmacological sciences. 2004 Oct; 96(2):219-23. doi: 10.1254/jphs.scj04007x. [PMID: 15492462]
  • Hajime Ueshiba, Yukitaka Miyachi. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Internal medicine (Tokyo, Japan). 2004 Jul; 43(7):561-5. doi: 10.2169/internalmedicine.43.561. [PMID: 15335180]
  • Shunichi Kojima, Mikio Shida, Hiroyuki Yokoyama. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertension research : official journal of the Japanese Society of Hypertension. 2004 Jun; 27(6):379-85. doi: 10.1291/hypres.27.379. [PMID: 15253102]
  • Shinji Yagi, Seiichi Goto, Taro Yamamoto, Susumu Kurihara, Shigehiro Katayama. Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertension research : official journal of the Japanese Society of Hypertension. 2003 May; 26(5):383-7. doi: 10.1291/hypres.26.383. [PMID: 12887129]
  • Xiaoyan Zhou, Hidehiko Ono, Yuko Ono, Edward D Frohlich. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. Journal of hypertension. 2002 May; 20(5):993-1000. doi: 10.1097/00004872-200205000-00035. [PMID: 12011661]
  • H Tomiyama, Y Kimura, Y Kuwabara, C Maruyama, Y Yoshida, S Kuwata, T Kinouchi, H Yoshida, N Doba. Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertension research : official journal of the Japanese Society of Hypertension. 2001 Nov; 24(6):679-84. doi: 10.1291/hypres.24.679. [PMID: 11768727]
  • S Morimoto, K Takeda, A Oguni, H Kido, S Harada, J Moriguchi, H Itoh, T Nakata, S Sasaki, M Nakagawa. Reduction of white coat effect by cilnidipine in essential hypertension. American journal of hypertension. 2001 Oct; 14(10):1053-7. doi: 10.1016/s0895-7061(01)02159-8. [PMID: 11710785]
  • W Y Hu, N Fukuda, J Z Su, K Kanmatsuse. Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Journal of cardiovascular pharmacology. 2001 Sep; 38(3):450-9. doi: 10.1097/00005344-200109000-00013. [PMID: 11486249]
  • G W Rose, Y Kanno, H Ikebukuro, M Kaneko, K Kaneko, T Kanno, Y Ishida, H Suzuki. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertension research : official journal of the Japanese Society of Hypertension. 2001 Jul; 24(4):377-83. doi: 10.1291/hypres.24.377. [PMID: 11510750]
  • T Konda, A Takahara, K Maeda, H Dohmoto, R Yoshimoto. Effects of a dual L/N-type Ca(2+) channel blocker cilnidipine on neurally mediated chronotropic response in anesthetized dogs. European journal of pharmacology. 2001 Feb; 413(1):117-20. doi: 10.1016/s0014-2999(01)00738-5. [PMID: 11173070]
  • T Sugiura, E Imai, T Moriyama, M Horio, M Hori. Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron. 2000 May; 85(1):71-80. doi: 10.1159/000045633. [PMID: 10773759]
  • J E Ahaneku, K Sakata, T Uranol, Y Takada, A Takada. Effects of cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients. Drugs under experimental and clinical research. 2000; 26(4):119-23. doi: NULL. [PMID: 11109511]
  • J E Ahaneku, K Sakata, T Urano, Y Takada, A Takada. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during treatment of hypertension with cilnidipine. Pharmacological research. 2000 Jan; 41(1):81-4. doi: NULL. [PMID: 10600273]
  • N Harada, M Ohnaka, S Sakamoto, Y Niwa, Y Nakaya. Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM. Cardiovascular drugs and therapy. 1999 Nov; 13(6):519-23. doi: 10.1023/a:1007827720807. [PMID: 10686661]
  • K Sakata, M Shirotani, H Yoshida, R Nawada, K Obayashi, K Togi, N Miho. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension (Dallas, Tex. : 1979). 1999 Jun; 33(6):1447-52. doi: 10.1161/01.hyp.33.6.1447. [PMID: 10373231]
  • S Takeda, H Ueshiba, Y Hattori, M Irie. Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Diabetes research and clinical practice. 1999 Jun; 44(3):197-205. doi: 10.1016/s0168-8227(99)00053-4. [PMID: 10462143]
  • A Karasawa, H Nomura, M Nito, R Sonoda, H Tanaka, N Kosaka, K Yamaguchi, S Kobayashi. [Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1999 May; 113(5):317-26. doi: 10.1254/fpj.113.317. [PMID: 10480159]
  • A Takahara, H Dohmoto, H Hisa, S Satoh, R Yoshimoto. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Japanese journal of pharmacology. 1997 Sep; 75(1):27-32. doi: 10.1254/jjp.75.27. [PMID: 9334883]
  • M Dozen, K Watanabe, M Hosono, Y Hayashi. [Effect of cilnidipine on renal function in SHR and endothelin-induced renal dysfunction]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1996 Feb; 107(2):79-89. doi: 10.1254/fpj.107.79. [PMID: 8721010]
  • M Hosono, S Fujii, T Hiruma, K Watanabe, Y Hayashi, H Ohnishi, Y Takata, H Kato. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Japanese journal of pharmacology. 1995 Oct; 69(2):127-34. doi: 10.1254/jjp.69.127. [PMID: 8569049]
  • M Hosono, T Hiruma, K Watanabe, Y Hayashi, H Ohnishi, Y Takata, H Kato. Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats. Japanese journal of pharmacology. 1995 Oct; 69(2):119-25. doi: 10.1254/jjp.69.119. [PMID: 8569048]
  • A Takahara, H Uchida, T Konda, H Dohmoto, R Yoshimoto, M Komori, T Morioka, I Ono, Y Takata, H Kato. [Antihypertensive effects of repeated oral administration of cilnidipine, a novel calcium antagonist, in 2K1C renal hypertensive dogs]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1995 Oct; 106(4):279-87. doi: 10.1254/fpj.106.279. [PMID: 8537075]
  • K Hatada, M Kimura, I Ono, M Ozaki. Determination of a new calcium antagonist and its main metabolite in plasma by thermospray liquid chromatography-mass spectrometry. Journal of chromatography. 1992 Nov; 583(1):116-21. doi: 10.1016/0378-4347(92)80352-q. [PMID: 1484084]